Gene: CPSF4L

642843
-
cleavage and polyadenylation specific factor 4 like
protein-coding
17q25.1
Ensembl:ENSG00000187959 Vega:OTTHUMG00000132640 UniprotKB:A6NMK7
NC_000017.11
PubMed
0   ANCO-SNPs
ND
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
3.910e-2 (AD)  2.243e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
SULT1C40.575
STK330.554
HSDL20.548
FAM227B0.546
LEPROT0.543
LIX10.54
CHDH0.538
ERBB20.536
NPAS30.535
BMPR1B0.532

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
VIT-0.405
AGMAT-0.403
THEM5-0.383
LRRC38-0.381
SYNPO2-0.381
GALNT14-0.38
CACNA1F-0.374
TUBA8-0.372
KCNS3-0.364
RASGEF1C-0.36

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0297902,2',3',4,4',5-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CPSF4L mRNA"25510870
C0817662,4,4'-trichlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CPSF4L mRNA"25510870
C0140242,4,5,2',4',5'-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CPSF4L mRNA"25510870
C0098282,4,5,2',5'-pentachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CPSF4L mRNA"25510870
C0094072,5,2',5'-tetrachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CPSF4L mRNA"25510870
D000082AcetaminophenAcetaminophen affects the expression of CPSF4L mRNA17562736
D016604Aflatoxin B1Aflatoxin B1 results in increased methylation of CPSF4L gene27153756
C018475butyraldehydebutyraldehyde results in decreased expression of CPSF4L mRNA26079696
D002994ClofibrateClofibrate results in increased expression of CPSF4L mRNA23811191
D002945Cisplatin[Cisplatin co-treated with jinfukang] results in increased expression of CPSF4L mRNA27392435
D002945CisplatinCisplatin results in increased expression of CPSF4L mRNA27392435
C039281furanfuran results in decreased expression of CPSF4L mRNA24183702
C544151jinfukang[Cisplatin co-treated with jinfukang] results in increased expression of CPSF4L mRNA27392435
C544151jinfukangjinfukang results in increased expression of CPSF4L mRNA27392435
D037742Nanotubes, Carbon"Nanotubes, Carbon affects the expression of CPSF4L mRNA"25620056
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in increased expression of CPSF4L mRNA"25620056
C410127PCB 180"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CPSF4L mRNA"25510870
D010634PhenobarbitalPhenobarbital results in increased expression of CPSF4L mRNA19270015
C006253pirinixic acidpirinixic acid results in increased expression of CPSF4L mRNA18301758|2381119
C045950propiconazolepropiconazole results in decreased expression of CPSF4L mRNA21278054
C057693troglitazonetroglitazone results in decreased expression of CPSF4L mRNA28973697
D014520UrethaneUrethane results in decreased expression of CPSF4L mRNA28818685
D001335Vehicle EmissionsVehicle Emissions results in decreased methylation of CPSF4L gene25560391

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0003723RNA binding-IBA21873635  
GO:0004521endoribonuclease activity-IBA21873635  
GO:0046872metal ion binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0006378mRNA polyadenylation-IBA21873635  
GO:0090502RNA phosphodiester bond hydrolysis, endonucleolytic-IEA-  
GO:0098789pre-mRNA cleavage required for polyadenylation-IBA21873635  
GO ID GO Term Qualifier Evidence PubMed
GO:0005847mRNA cleavage and polyadenylation specificity factor complex-IBA21873635  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
29762635An Epigenome-Wide Association Study (EWAS) of Obesity-Related Traits. (2018 May 14)Dhana KAm J Epidemiol